Guidance
First malaria vaccine in Africa: A potential new tool for child health and improved malaria control
A first generation vaccine known as RTS,S/AS01 (RTS,S) acts against Plasmodium falciparum, the most deadly malaria parasite globally and the most prevalent in Africa. The vaccine provides partial protection against malaria among young African children, the population most affected by the disease. Rigorous clinical testing in 7 African countries has shown its potential to boost malaria prevention and save lives.
The Malaria Vaccine Implementation Programme (MVIP) was established by WHO to coordinate and support the introduction of the vaccine in selected areas of Africa through country-led routine immunization. The Programme will evaluate the vaccine’s public health impact in the context of routine use and inform policy about its potential deployment on a broader scale.
Authors
Languages
- English
Publication year
2019
Publisher
WHO
Type
Guidance
Categories
- Programme management
Diseases
- Malaria
Countries
- Africa
Organisations
- World Health Organization (WHO)
EPI-CORE-MALARIA
| Title | Author | Year | Type | Language |
|---|---|---|---|---|
| Q&A on the Phase 3 trial results for malaria vaccine RTS,S/AS01 | World Health Organization (WHO) | 2017 | Repository | English |
| Q&A on the malaria vaccine implementation programme (MVIP) | World Health Organization (WHO) | 2019 | Guidance | English |
| First malaria vaccine in Africa: A potential new tool for child health and improved malaria control | World Health Organization (WHO) | 2019 | Guidance | English |
| Malaria vaccine: WHO position paper – May 2024 | World Health Organization (WHO) | 2024 | Journal article | English |
